EVENTS

Date:	Friday, May 8, 2009
Time:	10:00 AM -- 12:00 PM
Location:	Wohlstetter Conference Center, Twelfth Floor, AEI 1150 Seventeenth Street, N.W., Washington, D.C. 20036

 

Speaker biographies

Ernst R. Berndt is the Louis E. Seley Professor in Applied Economics at the MIT Sloan School of Management and codirector of the Harvard-MIT Biomedical Enterprise Program. He serves as director of the National Bureau of Economic Research Program on Technological Progress and Productivity Measurement and, until recently, was chair of the Federal Economic Statistics Advisory Committee, an interagency committee formed by the Bureau of Labor Statistics, the Bureau of Economic Analysis, and the U.S. Census Bureau. Mr. Berndt also served as a member of the National Science Foundation Panel on Measurement, Methodology, and Statistics. Currently, he serves on the editorial board of Health Affairs. Mr. Berndt's health care research has been published in peer-reviewed journals such as the New England Journal of Medicine, The American Journal of Psychiatry, The Journal of Mental Health Policy and Economics, the Journal of Health Economics, and Health Affairs. In 1985, he was named the most cited economist under age forty. In the last decade, much of Mr. Berndt's research has focused on economic issues in health care, with a strong emphasis on measurement of costs, outcomes, and prices.

John E. Calfee is a resident scholar at AEI. He previously worked on the economics of consumer protection--including advertising and marketing, the tort liability system, tobacco, and other topics--at the Bureau of Economics at the Federal Trade Commission. He has taught marketing and consumer behavior at the business schools of the University of Maryland at College Park and Boston University and spent a year as a visiting senior fellow at the Brookings Institution. Mr. Calfee's academic articles and opinion pieces cover a variety of topics, including tort liability, advertising and information, Food and Drug Administration (FDA) regulation, and the pharmaceutical market. His op-eds have run in the Wall Street Journal, the Philadelphia Inquirer, the Los Angeles Times, and numerous other newspapers and magazines. His recent scholarly publications have appeared in Clinical Pharmacology and Therapeutics, Health Affairs, and the Supreme Court Economic Review. He has published three short books: Fear of Persuasion: A New Perspective on Advertising and Regulation (AEI Press, 1997); Prices, Markets, and the Pharmaceutical Revolution (AEI Press, 2000); and Biotechnology and the Patent System: Balancing Innovation and Property Rights, with Claude Barfield (AEI Press, 2007). He has also testified before Congress and federal agencies on various topics, including alcohol advertising; biodefense vaccine research; international drug prices; the Vioxx episode; and, most recently, FDA oversight of drug safety.

Scott Gottlieb, M.D., is a practicing physician and a resident fellow at AEI. A leading expert in health care policy, Dr. Gottlieb's work focuses on providing insights into the economic, regulatory, and technological forces driving the transformation of health care today. From 2005 to 2007, Dr. Gottlieb served as Food and Drug Administration (FDA) deputy commissioner and, from 2003 to 2004, as a senior adviser to then–FDA commissioner Mark McClellan and as the FDA's director of medical policy development. A recipient of numerous medical association awards, Dr. Gottlieb is the author of more than three hundred articles that have appeared in leading medical journals, as well as the Wall Street Journal, the New York Times, USA Today, and Forbes. Dr. Gottlieb has held editorial positions on the British Medical Journal and the Journal of the American Medical Association and appears regularly as a guest commentator on CNBC. Previously, Dr. Gottlieb worked as a health care analyst for the investment bank Alex Brown & Sons and authored the Forbes-Gottlieb Medical Technology Letter and the Gilder Biotech Report. Dr. Gottlieb has testified as an expert witness on health and regulatory matters before the U.S. Senate and House of Representatives and members of the Japanese Diet.

Henry Grabowski has been at Duke University since 1972, where he is a professor of economics and the director of the Program in Pharmaceuticals and Health Economics. He has also served on the faculty of Yale University and held visiting appointments at the Health Care Financing Administration in Washington, D.C., and the International Institute of Management in Berlin, Germany. Mr. Grabowski has published numerous studies on the pharmaceutical industry, with his principal research involving the economics of the innovation process, business regulation, and industrial organization. He has investigated the economics of pharmaceutical research and been an adviser and consultant to several organizations, including the National Academy of Sciences, the Institute of Medicine, the Federal Trade Commission, the Government Accountability Office, and the Office of Technology Assessment.

Anjli C. Warner is currently the lead market forecaster for the anemia drug Aranesp at Amgen in Thousand Oaks, California. Prior to joining Amgen in 2007, Mrs. Warner was a manager at Elan Pharmaceuticals in its corporate strategy group, where she analyzed licensing and acquisition opportunities by conducting market assessments, benchmarking competitors, and forecasting financials. Previously, she was a senior analyst in the strategy and analysis group at Digitas, where she developed and recommended cross-channel marketing strategies for General Motors. Prior to Digitas, Mrs. Warner worked at Morgan Stanley in global equity capital markets for health care, energy, and consumer products industries.